title: [Pleiotropic effects of statins on endothelium and signaling mechanisms].
authors.forename: Masayuki
authors.initials: M
authors.lastname: Shiota
authors.forename: Yasukatsu
authors.initials: Y
authors.lastname: Izumi
authors.forename: Takafumi
authors.initials: T
authors.lastname: Nakao
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iwao
mesh_terms: D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1 / Q000096:biosynthesis / Q000235:genetics; D004730:Endothelium, Vascular / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009569:Nitric Oxide / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III / Q000235:genetics / Q000378:metabolism; D010597:Pharmacogenetics; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics / Q000378:metabolism; D013729:Terpenes / Q000378:metabolism
chemical_list: D019332:Endothelin-1; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D017395:Plasminogen Activator Inhibitor 1; D013729:Terpenes; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III; D019869:Phosphatidylinositol 3-Kinases